Table 3. Associations between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and mortality among hepatocellular carcinoma patients with T2DM^*.

	Sensitivity analysis 1		Sensitivity analysis 2		Sensitivity analysis 3
	Deaths/Patients	HR (95% CI)	Deaths/Patients	HR (95% CI)	Deaths/Patients	HR (95% CI)
SGLT2 inhibitor use
No	86/137	Reference	88/137	Reference	77/122	Reference
Yes	78/137	0.50 (0.37–0.69)	78/137	0.78 (0.57–1.08)	74/122	0.78 (0.55–1.10)
Duration of use
<12 months	51/85	0.52 (0.37–0.75)	51/85	0.89 (0.62–1.29)	48/67	0.86 (0.58–1.29)
≥ 12 months	27/52	0.47 (0.30–0.74)	27/52	0.63 (0.40–0.998)	26/55	0.66 (0.41–1.07)

*Models were adjusted for age at diagnosis, sex, race/ethnicity, marital status, chronic conditions (chronic kidney disease, hypertension, cardiovascular disease), cancer stage, cancer treatment (cancer-directed surgery, chemotherapy, radiation), diabetes duration (<5 years, 5-<10 years, 10 or more years), metformin use, hepatitis C virus infection, hepatitis B virus infection, alcohol-related diseases, and cirrhosis.

Sensitivity analysis 1 –employed propensity score among SGLT2i users and non-users and then matched the two groups by propensity score with a caliper of 0.04 standard deviation of propensity score.

Sensitivity analysis 2 –employed propensity score among SGLT2i users and DPP4i users and then matched the two groups by propensity score with a caliper of 0.12 standard deviation of propensity score.

Sensitivity analysis 3 –employed propensity score among SGLT2i users and DPP4i users and then matched the two groups by propensity score with a caliper of 0.12 standard deviation of propensity score and distance between HCC diagnosis and initiation of the two compared drugs (± 3 months).